Overview

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DWP16001 After Oral Administration in Healthy Male Volunteers

Status:
Completed

Trial end date:
2019-07-30

Target enrollment:

Participant gender:

Summary

This is a dose block-randomized, double-blind, placebo- and active-controlled, single and multiple dosing, dose-escalation clinical phase 1 trial to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of DWP16001 after oral administration in healthy male volunteers.

Phase:

Phase 1

Details

Lead Sponsor:

Daewoong Pharmaceutical Co. LTD.

Treatments:

Dapagliflozin